Development of Therapeutics for DENGUE VIRUS

登革热病毒治疗方法的开发

• 批准号: 10938081
• 金额: $ 175.3万
• 依托单位: ABVIRO, LLC
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-25 至 2024-06-24
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10938081
• 关键词: Advanced Development; Categories; Chemistry; Clinical; Dengue Virus; Development; Emerging Communicable Diseases; National Institute of Allergy and Infectious Disease; Pathway interactions; efficacy evaluation; manufacture; pre-clinical; priority pathogen; product development; research and development; safety assessment; therapeutic candidate; therapeutic development

To support the advanced development of a promising candidate therapeutic for NIAID Category A, B, and C Priority Pathogens or emerging infectious diseases. The research and development activities to be supported will allow the candidate therapeutic product to progress through the product development pathway, and include preclinical and IND enabling development activities, chemistry optimization/development, GMP manufacturing, and clinical safety and efficacy assessment.

为了支持NIAID类别A，B和C优先病原体或新兴传染病的有前途的候选候选治疗。要支持的研究和开发活动将使候选人的治疗产品能够通过产品开发途径进行进展，并包括临床前和IND启用开发活动，化学优化/开发，GMP制造以及临床安全和效率评估。